ЖЕРАР Катрин Мари Гислен (BE),ЛАКЕРР Сильви (US),ЛЕБОВИТЧ Питер Ф. (US),ЛЕМАНН Фредерик Франсуа Эжен (BE),ЛУАХЕД Ямила (BE)
申请号：
RU2014122867
公开号：
RU2014122867A
申请日:
2012.12.19
申请国别(地区):
RU
年份:
2016
代理人:
摘要：
1. A method of treating susceptible cancer in a person in need thereof, comprising administering a therapeutically effective amount of (1) an immunotherapeutic agent specific for MAGEA3 (melanoma-associated antigen 3), and (2) one or both of the compounds of (a) a compound of the formula (I) or a pharmaceutically acceptable salt thereof； and (b) a compound of structural formula (II) or a pharmaceutically acceptable salt or solvate thereof. 2. A method according to claim 1, wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is in the form of a methanesulfonate salt. A method according to claim 1 or 2, wherein the compound of structural formula (I) is in the form of a solvate with dimethyl sulfoxide. The method of claim 1, wherein the immunotherapeutic agent specific for MAGEA3 is a fusion protein, D-MAGE-A3.5. The method of claim 1, wherein the immunotherapeutic agent specific for MAGEA3 is a fusion protein comprising SEQ ID NO: 2.6. The method of claim 1, wherein the immunotherapeutic agent specific for MAGEA3 contains an adjuvant. The method of claim 1, wherein the compound of formula (I) and / or (II) or a pharmaceutically acceptable salt thereof further comprises a pharmaceutically acceptable diluent or carrier. The method of claim 1, wherein the cancer is selected from head and neck cancer, breast cancer, lung cancer, colon cancer, ovarian cancer, prostate cancer, non-small cell lung cancer (NSCLC), gliomas, glioblastoma, astrocyte, glioblastoma multiforme, syndrome Banyan-Zonan, Cowden's disease, Lermitt-Duclos disease, inflammatory breast cancer, Wilms tumor, Ewing's sarcoma, rhabdomyosarcoma, ependymoma, medulloblastoma, kidney cancer, liver cancer, melanoma, pancreatic cancer, sarcoma, osteosarcoma, gig1. Способ лечения чувствительного рака у человека, нуждающегося в этом, включающий введение терапевтически эффективного количества (1) иммунотерапевтического средства, специфичного в отношении MAGEA3 (меланома-ассоциированный ант
